By Hendra Lukman 
A revolutionary gene therapy, developed by scientists at University College London (UCL) and Great Ormond Street Hospital (GOSH), is demonstrating remarkable promise for individuals, both children and adults, battling T-cell acute lymphoblastic leukemia (T-ALL). This aggressive and uncommon blood cancer, which progresses rapidly, has historically presented significant treatment challenges, often leaving patients with severely limited therapeutic options. The innovative approach leverages genome-edited immune cells, specifically T-cells, engineered to precisely target and eradicate the disease, marking a significant advancement in the fight against this formidable malignancy.
The Genesis of BE-CAR7: A Paradigm Shift in Cancer Therapy
The pioneering gene therapy, christened BE-CAR7, represents a first-of-its-kind application of base-editing technology to combat T-cell leukemias that have proven resistant to conventional treatments. Base-editing, an advanced iteration of CRISPR gene-editing technology, allows for the precise alteration of individual DNA "letters" within living cells, offering unparalleled accuracy and minimizing the risk of unintended genetic modifications. This technology is crucial in overcoming the inherent complexities of treating T-cell malignancies.
The journey of BE-CAR7 began in 2022 when researchers at GOSH and UCL administered this groundbreaking therapy to Alyssa, a 13-year-old girl from Leicester. This historic moment marked the first time a base-edited therapy was deployed in a patient globally, ushering in a new era of personalized cancer treatment. Since Alyssa’s initial treatment, the therapy has been extended to eight additional children and two adults at GOSH and King’s College Hospital (KCH), expanding the cohort of patients benefiting from this innovative approach.
Clinical Trial Unveils Striking Remission Rates
The early findings from the clinical trial investigating BE-CAR7 have been rigorously analyzed and published in the prestigious New England Journal of Medicine. These pivotal results were also presented at the 67th American Society of Hematology Annual Meeting, underscoring the scientific community’s keen interest in this therapeutic breakthrough. The research team reported several key outcomes, highlighting the therapy’s efficacy:
- High Remission Rates: The trial data revealed significantly high rates of remission among patients treated with BE-CAR7. For many, this represented a crucial turning point, offering a chance at disease clearance where previous treatments had failed.
- Safety Profile: While all intensive cancer therapies carry risks, the base-editing approach, by not cutting DNA, demonstrated a reduced potential for chromosomal damage compared to earlier gene-editing methods. This contributed to a manageable safety profile in the initial patient group.
- Feasibility of "Off-the-Shelf" Cells: A critical aspect of the BE-CAR7 development is the creation of "universal" or "off-the-shelf" CAR T-cells. These cells, derived from healthy donors, can be manufactured in advance and stored, making them readily available for immediate use in eligible patients, thus bypassing the time-consuming process of creating patient-specific CAR T-cells.
Understanding CAR T-Cell Therapy: A Targeted Immune Assault
Chimeric Antigen Receptor (CAR) T-cell immunotherapy has emerged as a formidable weapon in the arsenal against various blood cancers. This sophisticated treatment modality involves genetically modifying a patient’s own T-cells. These T-cells are engineered to express a synthetic receptor, the CAR, which is designed to recognize and bind to specific protein markers, or "flags," found on the surface of cancer cells. Once armed with the CAR, these modified T-cells can effectively identify, attack, and destroy malignant cells, while largely sparing healthy tissues.
However, developing CAR T-cell therapies for leukemias originating in T-cells (T-ALL) has presented a unique and formidable challenge. The inherent difficulty lies in designing a treatment that can effectively eliminate cancerous T-cells without inadvertently triggering the engineered CAR T-cells to attack the body’s own healthy T-cell population, a phenomenon known as "on-target, off-tumor" toxicity or fratricide.
Base-Editing: The Key to Universal CAR T-Cells
The innovation of BE-CAR7 lies in its utilization of a next-generation genome editing technique that avoids making double-strand breaks in the DNA. This sophisticated approach significantly reduces the likelihood of chromosomal abnormalities and associated risks. Employing CRISPR-based tools, researchers meticulously altered single DNA letters within the cells, effectively reprogramming them. This precise editing capability enabled the team, in 2022, to establish banked stores of "universal" CAR T-cells. These "off-the-shelf" cells are designed to be compatible with a broad range of patients, retaining their ability to recognize and neutralize T-cell leukemia.
The creation of these universal BE-CAR7 T-cells involved a meticulously orchestrated process. The T-cells were sourced from the white blood cells of healthy donors. The intricate engineering steps were carried out within a state-of-the-art clean room facility at GOSH. This sophisticated manufacturing process utilized custom RNA, messenger RNA (mRNA), and a lentiviral vector, all integrated into an automated system that the research team had previously refined. The key stages of this manufacturing process included:
- Cell Isolation and Expansion: Healthy donor T-cells were carefully isolated and expanded in culture to generate a sufficient quantity for editing and subsequent administration.
- Base Editing of T-cells: The cells underwent precise base-editing to introduce the necessary genetic modifications, including the insertion of the CAR gene and any necessary "safety" edits to prevent fratricide.
- Quality Control and Cryopreservation: Rigorous quality control measures were implemented at each stage to ensure the purity, potency, and safety of the edited cells. The final product was then cryopreserved, allowing for long-term storage and readiness for patient use.
The Therapeutic Journey: From Cancer Clearance to Immune Reconstitution
Once administered to patients, the base-edited BE-CAR7 T-cells embark on a targeted mission. They swiftly identify and eliminate T-cells throughout the body, with a particular focus on eradicating the leukemia cells. In cases where the leukemia is successfully cleared within the initial month of treatment, patients then proceed to a bone marrow transplant. This crucial step aims to restore a fully functional immune system, which can be compromised by the intense therapy and the underlying disease. The reconstitution of the immune system typically occurs over the subsequent months, allowing patients to begin rebuilding their health.
Professor Waseem Qasim, the lead researcher and a distinguished professor of cell and gene therapy at UCL, as well as an honorary consultant immunologist at GOSH, expressed profound optimism about the findings. "We previously demonstrated encouraging results using precision genome editing for children with aggressive blood cancer, and this expanded cohort of patients further validates the significant impact of this therapeutic approach," Professor Qasim stated. "Our work has confirmed that universal or ‘off the shelf’ base-edited CAR T-cells are capable of seeking out and destroying highly resistant forms of CD7+ leukemia."
Professor Qasim also acknowledged the complex emotional landscape surrounding such intensive treatments. "Numerous teams across the hospital and university collaborated on this endeavor, and we are immensely proud of the patients who have achieved disease clearance. However, we are also deeply aware that the outcomes have not been as hoped for all children," he added. "These are demanding and challenging treatments, and patients and their families have shown remarkable generosity in recognizing the importance of learning from every experience to advance future therapies."
A Beacon of Hope for Refractory T-ALL
Dr. Rob Chiesa, a key investigator in the study and a consultant in bone marrow transplantation at GOSH, highlighted the critical need for novel therapies for a subset of T-ALL patients. "While the majority of children diagnosed with T-cell leukemia respond well to standard treatments, approximately 20% do not achieve remission or relapse," Dr. Chiesa explained. "These patients are in desperate need of more effective options, and this research offers a tangible glimmer of hope for improved prognoses for all individuals diagnosed with this rare yet aggressive blood cancer."
Dr. Chiesa further emphasized the profound impact of the treatment on patients like Alyssa. "Witnessing Alyssa’s remarkable recovery is incredibly inspiring and a testament to her resilience and the unwavering dedication of a vast team at GOSH. The seamless collaboration between bone marrow transplant specialists, hematologists, ward staff, educators, play therapists, physiotherapists, laboratory teams, and research personnel is fundamental to providing comprehensive support to our patients."
Echoing this sentiment, Dr. Deborah Yallop, a consultant hematologist at KCH, remarked on the therapy’s potency. "We have observed impressive responses in clearing leukemia that previously appeared incurable. This represents a truly powerful and transformative approach to treating this challenging disease."
Expanding Access: Funding Fuels Future Trials
The ongoing clinical trial is proudly sponsored by GOSH and receives vital support from organizations including the Medical Research Council, Wellcome, and the National Institute for Health and Care Research (NIHR). For patients eligible for NHS care and interested in participating, discussions with their healthcare team are encouraged to explore potential involvement in ongoing trials.
In a significant development aimed at broadening access, GOSH Charity has pledged substantial funding to support the treatment of an additional 10 T-ALL patients. This investment, exceeding £2 million, will not only facilitate wider participation in the trial but also bolster GOSH Charity’s ambitious fundraising campaign for a new Children’s Cancer Centre. This state-of-the-art facility is envisioned to accelerate cutting-edge research and drive further innovations in pediatric oncology.
Alyssa’s Journey: A Symbol of Resilience and Progress
Alyssa Tapley, now 16 years old, stands as a living testament to the transformative power of this novel therapy. Her courageous decision to participate in the trial as the first-ever recipient of base-edited cell therapy has paved the way for countless others. In 2022, she shared her story when her leukemia was undetectable, though she remained under close medical surveillance. Today, Alyssa has transitioned to long-term follow-up and is fully immersed in a vibrant daily life, actively engaging with her peers and pursuing her passions.
Her battle with T-cell leukemia began in May 2021, following months of symptoms that were initially misattributed to recurrent viral illnesses and fatigue. Standard treatments, including chemotherapy and a bone marrow transplant, proved unsuccessful, and discussions about palliative care were underway when the research team offered her the experimental BE-CAR7 therapy.
Reflecting on her decision to join the trial, Alyssa shared, "I chose to participate in the research because I felt that even if it didn’t work for me, it could potentially help others. Years later, we know it worked, and I am doing exceptionally well. I’ve been able to experience so many things that are typical for a teenager." She elaborated, "I’ve gone sailing, spent time away from home working on my Duke of Edinburgh Award, and even just attending school is something I once only dreamed of when I was ill. I truly appreciate every moment and don’t take anything for granted." Her aspirations for the future are as inspiring as her recovery: "Next on my list is learning to drive, but my ultimate goal is to become a research scientist and be part of the next groundbreaking discovery that can help people like me."
Sustained Research Infrastructure and Collaborative Support
The successful manufacturing of BE-CAR7 cells is the culmination of a long-term research program housed within the UCL Great Ormond Street Institute of Child Health, under the leadership of Professor Qasim. This institute, a pioneering center for childhood health research, benefits from the expertise of its researchers and clinicians, many of whom also hold honorary consultant positions at GOSH. The development of these innovative genome editing treatments has been significantly bolstered by the steadfast support from the NIHR, Wellcome, the Medical Research Council, and GOSH Charity.
The research team now operates from the state-of-the-art Zayed Centre for Research into Rare Disease in Children. This cutting-edge facility is a testament to a visionary partnership between UCL and GOSH, made possible by a generous £60 million gift in 2014 from Her Highness Sheikha Fatima bint Mubarak, in honor of her late husband, Sheikh Zayed bin Sultan Al Nahyan. The center provides a world-class environment for research and clinical translation, fostering collaboration and accelerating the pace of discovery.
The researchers extended their heartfelt gratitude to Anthony Nolan, an organization dedicated to stem cell donation and research, and to the countless volunteer blood and stem cell donors whose generosity is fundamental to advancing such life-saving therapies. They also expressed profound appreciation for the patients and families who bravely chose to participate in this groundbreaking work, contributing invaluable insights and data that are driving progress in the fight against T-ALL.
